Medizone Home
×

Ranbaxy launches first Biosimilar Infliximab in India!

Ranbaxy Laboratories Limited (Ranbaxy), one of India’s largest pharmaceutical company, announced on 1.12.2014 the launch of Infimab (BOW015), the first Remicade (infliximab) biosimilar in India.

Infimab, is being introduced in the Indian market through a licensing partnership with Epirus Biopharmaceuticals, Inc. a US and Swiss-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies. Infimab will be manufactured by Reliance Life Sciences at a facility in Mumbai. The innovator reference product is currently marketed for the treatment of inflammatory diseases including rheumatoid arthritis, Crohn’s Disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis and psoriasis.

Infimab marks Ranbaxy’s entry into mAb (Monoclonal Antibodies) biologics, and will help the company provide greater access to quality biologic medicines in management of conditions like rheumatoid arthritis.

Source: Ranbaxy press release